Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://covid19.nih.gov/

Principal Investigator
Name
Paul A. Kvale
Institution
Henry Ford Health System
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
2008-0027
Initial CDAS Request Approval
Jun 17, 2008
Title
Lung Interval Cancers
Summary
This is a descriptive study to characterize the participants in PLCO who have been diagnosed with lung cancer as a result of the chest x-ray screening, and to compare the characteristics of those patients and their lung cancers to patients who developed lung cancers in the intervals between chest x-ray screening. In the intervention arm there are currently 307 lung cancers diagnosed by chest x-ray screening, and 150 interval lung cancers. Understanding the epidemiology, clinical behavior and biology of lung cancers detected by screening and those which escape detection is important for developing strategies to reduce lung cancer mortality.
Aims

1. Describe the demographic features of the patients who had screen-detected lung cancers. 2. Describe the lung cancers by histology and stage for screen-detected lung cancers. 3. Describe the demographic features of the patients who had lung cancers that were diagnosed in the intervals between chest x-ray screening. 4. Describe the lung cancers by histology and stage for the interval lung cancers. 5. Compare cancers in screen vs interval detection.

Collaborators

Neil Caporaso (NCI)
John Commins (IMS)
Paul Kvale (Henry Ford Health System)
Tom Riley (IMS)